PCI Synthesis establishes a cGMP Advanced Polymer Development and Manufacturing Group

The team has experience with developing polymeric materials for implantable medical devices, drug delivery technologies, therapeutics, excipients and medical grade coatings

US firm PCI Synthesis has formed a cGMP Advanced Polymer Development and Manufacturing Group, which is currently developing and manufacturing more than a dozen advanced polymer-based projects.

The independent cGMP contract manufacturing organisation (CMO), which is based in Newburyport, MA, says the addition of an advanced polymer-based materials development and manufacturing capability significantly expands its customer base and reach within this growing market.

The team currently includes polymer chemists with expertise in the development, scale up, and cGMP manufacturing of these materials. The team is also supported by PCI Synthesis’s existing Kilo Lab team.

Products in development include a broad range of polymer-based materials, including: implantable medical devices including biodegradable implants; nano-polymer particle technology; combination API and polymer technologies; drug delivery technologies; therapeutics and excipients and medical grade coatings.

The new Advanced Polymer Manufacturing Group operates out of the company’s development lab in Devens, MA, and collaborates with PCI Synthesis' cGMP facilities in Newburyport.